Vanguard Capital Management’s Enveric Biosciences ENVB Stock Holding History

Vanguard Capital Management’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.6K	Buy	+14,912	New	+$35.8K	﹤0.01%	4009

Other funds holding ENVB

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

Vanguard Capital Management's ENVB Position: Q2 2026 in Review

Vanguard Capital Management opened a new position in Enveric Biosciences (ENVB) in Q2 2026: 14,912 shares worth $20.6K. The stake represents ﹤0.01% of the portfolio and ranks #4009 among its holdings.

15 funds tracked by Wall St. Rank hold ENVB as of Q2 2026.

Vanguard Capital Management held 14,912 shares of Enveric Biosciences worth $20.6K as of Q2 2026.
Enveric Biosciences was a new Vanguard Capital Management position in Q2 2026.
Enveric Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #4009 holding.
15 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.